May 10, 2017 | Medical Communications, medical education, rare diseases, recruitment
As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*.
The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death.
Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.”
Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.
“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.”
Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients.
Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU. For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com.
* EvaluatePharma Orphan Drug Report 2015
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
In this month’s Smart Thinking blog on PM.Live.com, Michelle Sweet, Learning and Development Consultant at Lucid Group, discusses the needs for a learner-led culture and a growth mindset in the...
Bluedog, a Lucid Group Company, has elevated and expanded its creative team into the US with the appointment of George Pearson as Client Solutions Director.George is a highly experienced medical...
The April issue of PME questions the meaning of ‘patient-centricity’ and whether we are achieving it.Patient-centricity has become a ubiquitous value within the pharmaceutical industry; however, is pharma delivering on...
Vivid Medical Communications, a Lucid Group company, is delighted to announce two magical additions to the team.Deborah Blain joins Vivid as an Account Manager. With over 10 years’ experience in...
Lucid’s Futures Executives were set the challenge of planning a magical Easter surprise across its seven offices. After an egg-citing (sorry!) brainstorm the grads chose three activities.- Egg-cellent Easter egg hunt- You’re...
Lucid Group continues to build its infrastructure in line with its ambitious growth plans by appointing Michael Joyce as Chief Financial Officer (CFO).Michael has considerable experience as a CFO and...
Great companies start with great leaders. However effective leadership requires skill, emotional intelligence, and most importantly, on-going self-improvement.With this in mind, Lucid Group has launched a new leadership programme for...
Leading Edge, a Lucid Group company, is delighted to announce the appointment of its new Lead Client Partnership Director, Frances O’Connor.Frances is an experienced strategic healthcare communicator with expertise in...
Amy Jackson, Editorial Director, Lucid Group discusses her unlikely path into Medical Communications.
Why pharma’s marketing metrics must close the loop